Seborrheic Dermatitis Clinical Trials
Here are the 6 most popular medical studies for seborrheic dermatitis
Monoclonal Antibodies
Lebrikizumab for Atopic Dermatitis
“ I tried so many drugs and nothing has worked long term. I have tried over 2 dozen topicals and oral steroids but have received no relief. I have been suffering for more than 10 years.”
Popular filter options for seborrheic dermatitis trials
Atopic Dermatitis Clinical Trials
View 75 Atopic Dermatitis medical studies.
Janus Kinase (JAK) Inhibitor
Abrocitinib for Atopic Dermatitis
This trial is studying whether a new drug, abrocitinib, is effective and safe for treating atopic dermatitis in patients aged 12 years and older. The trial consists of an initial treatment period of 92 weeks, followed by a secondary treatment period of variable length during which subjects will receive treatment with open-label abrocitinib until availability of commercial product in their country, or until the sponsor terminates the study in that country. There is also a sub-study evaluating whether abrocitinib has any potential effects on adolescent bone with regard to abnormal bone findings in knee MRI.
AD Clinical Trials
View 75 AD medical studies.
Janus Kinase (JAK) Inhibitor
Abrocitinib for Atopic Dermatitis
This trial is studying whether a new drug, abrocitinib, is effective and safe for treating atopic dermatitis in patients aged 12 years and older. The trial consists of an initial treatment period of 92 weeks, followed by a secondary treatment period of variable length during which subjects will receive treatment with open-label abrocitinib until availability of commercial product in their country, or until the sponsor terminates the study in that country. There is also a sub-study evaluating whether abrocitinib has any potential effects on adolescent bone with regard to abnormal bone findings in knee MRI.
Phase 3 Seborrheic Dermatitis Clinical Trials
View 99 phase 3 seborrheic dermatitis medical studies.
Janus Kinase (JAK) Inhibitor
Abrocitinib for Atopic Dermatitis
This trial is studying whether a new drug, abrocitinib, is effective and safe for treating atopic dermatitis in patients aged 12 years and older. The trial consists of an initial treatment period of 92 weeks, followed by a secondary treatment period of variable length during which subjects will receive treatment with open-label abrocitinib until availability of commercial product in their country, or until the sponsor terminates the study in that country. There is also a sub-study evaluating whether abrocitinib has any potential effects on adolescent bone with regard to abnormal bone findings in knee MRI.
Monoclonal Antibodies
Dupilumab for Atopic Dermatitis
This trial is testing the long-term safety and efficacy of dupilumab, a medication used to treat eczema, in children. The trial will also assess the levels of functional dupilumab in the blood after repeated treatment and the immunogenicity of the medication.
Seborrheic Dermatitis Clinical Trials With No Placebo
View 99 seborrheic dermatitis medical studies that do not have a placebo group.
Monoclonal Antibodies
Dupilumab for Atopic Dermatitis
This trial is testing the long-term safety and efficacy of dupilumab, a medication used to treat eczema, in children. The trial will also assess the levels of functional dupilumab in the blood after repeated treatment and the immunogenicity of the medication.
View More Seborrheic Dermatitis Trials
See another 79 many medical studies focused on seborrheic dermatitis.
Frequently Asked Questions
Introduction to seborrheic dermatitis
What are the top hospitals conducting seborrheic dermatitis research?
When it comes to finding innovative solutions for seborrheic dermatitis, several hospitals are leading the way in clinical research. In sunny Los Angeles, Dermatology Research Associates is at the forefront with an impressive 14 ongoing trials focused on this common skin condition. This dedicated institution is committed to investigating new treatments and improving the lives of those affected by seborrheic dermatitis. Meanwhile, First OC Dermatology in Fountain Valley has also positioned itself as a top contender, conducting ten active trials aimed at combating this bothersome condition that affects millions worldwide.
Down in San Antonio, Progressive Clinical Research is making significant strides with eight current seborrheic dermatitis trials. This Texas-based institute recognizes the importance of finding effective therapies for this chronic inflammatory disorder that commonly affects areas such as the scalp and face. Additionally contributing to the advancement of treatment options is Dawes Fretzin Clinical Research Group LLC in Indianapolis, where seven active studies are underway specifically targeting seborrheic dermatitis.
And let's not forget about Santa Monica's Clinical Science Institute, where groundbreaking research into seborrheic dermatitis is being conducted through seven ongoing clinical trials. With their collective efforts and dedication to understanding this frustrating skin condition better, these hospitals are offering hope to individuals who have long struggled with its symptoms.
Seborrheic dermatitis may seem like a minor inconvenience compared to other medical conditions; however, it can significantly impact one's quality of life due to its persistent nature and potential social implications. These pioneering institutions recognize that even seemingly benign conditions deserve attention and resources for improved management and patient comfort. Through their tireless pursuit of knowledge and innovation in treating seborrheic dermatitis, they bring us closer to effective remedies that will alleviate discomfort while restoring confidence in those affected by this often underestimated skin issue
Which are the best cities for seborrheic dermatitis clinical trials?
The best cities for seborrheic dermatitis clinical trials include Miami, Florida with 74 active studies focusing on Lebrikizumab, Nemolizumab, etrasimod, and other treatments. Los Angeles, California, Florida with 74 active studies focusing on Lebrikizumab, Nemolizumab, etrasimod, and other treatments. Los Angeles, California is another top city with 49 ongoing trials investigating Lebrikizumab, Upadacitinib, Nemolizumab, and additional interventions. Tampa in Florida follows closely behind with 48 active trials studying Nemolizumab, Lebrikizumab, AK002, and others. Each of these cities provides individuals suffering from seborrheic dermatitis access to cutting-edge clinical research that may lead to significant advancements in care.
Which are the top treatments for seborrheic dermatitis being explored in clinical trials?
Seborrheic dermatitis, a common skin condition characterized by redness and flaking, is the subject of ongoing clinical trials exploring potential treatments. Among the top contenders are:
- Ketoconazole: An antifungal medication showing promise in combating seborrheic dermatitis.
- Pimecrolimus: A nonsteroidal anti-inflammatory drug that may help alleviate symptoms associated with this condition.
- Ciclopirox olamine: An antifungal agent being investigated for its effectiveness in managing seborrheic dermatitis.
These treatments are part of a broader effort to find effective solutions for individuals suffering from seborrheic dermatitis, offering hope for improved quality of life and relief from the bothersome symptoms it presents.
What are the most recent clinical trials for seborrheic dermatitis?
Exciting advancements in the field of seborrheic dermatitis research are bringing new hope to those affected by this condition. Recent clinical trials have explored various treatment options, including a combination therapy that has shown promising results during Phase 2 testing. Additionally, Stage 1_PF-07275315 and IMG-007 Dose 1 have demonstrated potential benefits for treating seborrheic dermatitis patients, with both undergoing Phase 2 evaluation. Other studies have focused on evaluating the effectiveness of Dupilumab and Ruxolitinib in managing symptoms associated with seborrheic dermatitis. These ongoing trials hold promise in expanding our understanding of treatment possibilities and improving outcomes for individuals dealing with this challenging skin condition.
What seborrheic dermatitis clinical trials were recently completed?
A recent completion of a clinical trial brings hope for those affected by seborrheic dermatitis. Sponsored by Arcutis Biotherapeutics, Inc., the trial focused on evaluating the effectiveness of ARQ-154 in treating this common skin condition. Completed in June 2020, this milestone represents a step forward in identifying potential treatments to alleviate the symptoms and improve the quality of life for individuals with seborrheic dermatitis.